BioNTech SE American Depositary Share (BNTX)
BNTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/0001776985-26-000017-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-12-31. Converted from EUR at 0.8933 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | BNTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Germany |
| IPO year | 2019 |
| SEC CIK | 0001776985 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | 2M |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.2B |
| Net income | -$1.3B |
| Operating income | Not in SEC XBRL data |
| Net margin | -39.6% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 7.0× |
Reported in EUR; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-11-14 |
| Latest annual report | 20-F | 2026-03-10 |
| Latest quarterly / interim | 6-K | 2026-10-13 |
Source: SEC EDGAR submissions feed, 583 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.5% |
| 1 month | -7.9% |
| 3 months | -2.7% |
| Year to date | -6.4% |
| 1 year | -12.9% |
| From 52-week high | -25.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BIIB | Biogen Inc. | $228.90 | -0.22% | $33.8B |
| EXEL | Exelixis Inc. | $59.51 | -0.52% | $14.7B |
| NBIX | Neurocrine Biosciences Inc. | $135.13 | -4.41% | $13.7B |
| HALO | Halozyme Therapeutics Inc. | $109.62 | -1.31% | $12.4B |
| RVMD | Revolution Medicines Inc. | $188.44 | -2.84% | $40.4B |
| TECH | Bio-Techne Corp | $72.48 | -0.11% | $11.4B |
| PCVX | Vaxcyte Inc. | $66.80 | -5.45% | $10.5B |
| IBRX | ImmunityBio Inc. | $9.80 | -3.16% | $10.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier